Telix Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Telix Pharmaceuticals has a total shareholder equity of A$404.0M and total debt of A$11.9M, which brings its debt-to-equity ratio to 2.9%. Its total assets and total liabilities are A$746.0M and A$342.0M respectively. Telix Pharmaceuticals's EBIT is A$67.4M making its interest coverage ratio -64.7. It has cash and short-term investments of A$118.8M.
Key information
2.9%
Debt to equity ratio
AU$11.85m
Debt
| Interest coverage ratio | -64.7x |
| Cash | AU$118.84m |
| Equity | AU$403.97m |
| Total liabilities | AU$341.98m |
| Total assets | AU$745.96m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: T3X's short term assets (A$255.3M) do not cover its short term liabilities (A$258.4M).
Long Term Liabilities: T3X's short term assets (A$255.3M) exceed its long term liabilities (A$83.6M).
Debt to Equity History and Analysis
Debt Level: T3X has more cash than its total debt.
Reducing Debt: T3X's debt to equity ratio has reduced from 3.3% to 2.9% over the past 5 years.
Debt Coverage: T3X's debt is well covered by operating cash flow (419.4%).
Interest Coverage: T3X earns more interest than it pays, so coverage of interest payments is not a concern.